MX2023010317A - Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents
Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.Info
- Publication number
- MX2023010317A MX2023010317A MX2023010317A MX2023010317A MX2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A
- Authority
- MX
- Mexico
- Prior art keywords
- indole derivatives
- treatment
- agents useful
- disorders related
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010317A true MX2023010317A (es) | 2023-11-09 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010317A MX2023010317A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| MX2023010316A MX2023010316A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010316A MX2023010316A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166599A1 (enExample) |
| EP (2) | EP4301730A4 (enExample) |
| JP (2) | JP7894380B2 (enExample) |
| KR (2) | KR20230154219A (enExample) |
| CN (2) | CN117500788A (enExample) |
| AU (2) | AU2022229695A1 (enExample) |
| BR (1) | BR112023017754A2 (enExample) |
| CA (2) | CA3210270A1 (enExample) |
| IL (2) | IL305481A (enExample) |
| MX (2) | MX2023010317A (enExample) |
| WO (2) | WO2022183287A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| TW202519206A (zh) * | 2023-11-06 | 2025-05-16 | 大陸商宜昌人福藥業有限責任公司 | 一種n,n-二甲基色胺衍生物及其藥物組合物、製備方法和用途 |
| WO2025104490A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| HU225055B1 (en) * | 1990-10-15 | 2006-05-29 | Pfizer | Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds |
| ES2566056T3 (es) * | 2001-03-29 | 2016-04-08 | Eli Lilly And Company | N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6 |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| DK2753605T3 (da) * | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| WO2018094106A2 (en) * | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko active Pending
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A4/en active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en not_active Ceased
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko active Pending
- 2022-03-02 JP JP2023553660A patent/JP7894380B2/ja active Active
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en not_active Ceased
- 2022-03-02 EP EP22762290.9A patent/EP4301747A4/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4301747A4 (en) | 2025-01-22 |
| IL305622A (en) | 2023-11-01 |
| BR112023017754A2 (pt) | 2023-11-21 |
| EP4301730A1 (en) | 2024-01-10 |
| AU2022229695A1 (en) | 2023-09-28 |
| EP4301730A4 (en) | 2025-01-22 |
| JP2024508545A (ja) | 2024-02-27 |
| CA3210270A1 (en) | 2022-09-09 |
| CN117242065A (zh) | 2023-12-15 |
| JP2024508922A (ja) | 2024-02-28 |
| CN117500788A (zh) | 2024-02-02 |
| CA3210275A1 (en) | 2022-09-09 |
| EP4301747A1 (en) | 2024-01-10 |
| AU2022229037A1 (en) | 2023-09-28 |
| JP7894380B2 (ja) | 2026-07-23 |
| US20240166599A1 (en) | 2024-05-23 |
| WO2022183287A1 (en) | 2022-09-09 |
| KR20230154220A (ko) | 2023-11-07 |
| WO2022183288A1 (en) | 2022-09-09 |
| MX2023010316A (es) | 2023-11-09 |
| US20240166630A1 (en) | 2024-05-23 |
| IL305481A (en) | 2023-10-01 |
| KR20230154219A (ko) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551981A1 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| MX2023010316A (es) | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. | |
| MX2023006652A (es) | Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. | |
| MX2022009528A (es) | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. | |
| PE20210856A1 (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
| CO7230336A2 (es) | Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos | |
| ECSP066520A (es) | Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso | |
| MX2025001439A (es) | Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| PA8815001A1 (es) | Piridinil amidas para el tratamiento de trastornos del snc y metabolicos | |
| MX375978B (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2. | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| MX2024007938A (es) | Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead. | |
| MX2024012865A (es) | Derivados de indolina como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| NI202000029A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
| CO2019005090A2 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| CO2019004756A2 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| PE20160842A1 (es) | Piperidiniltetrahidroquinolinas sustituidas | |
| DOP2024000165A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2025001465A (es) | Dimeros de 3-pirrolidina-indol como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos | |
| UY31326A (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6 |